S1801- A Phase II Randomized Study Of Adjuvant Versus Neoadjuvant Mk-3475 (Pembrolizumab) For Clinically Detectable Stage III-Iv High Risk Melanoma
Posted Date: Oct 1, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The goal of this study is To compare event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant MK-3475 (pembrolizumab) with patients randomized to adjuvant MK-3475 (pembrolizumab)
Criteria:
To Be Eligible: Must Have Resectable Melanoma, >18 Years Of Age, No Other Active Infection Or Autoimmune Disease Needing Systemic Therapy, Nonpregnant/Nonbreastfeeding
Keywords:
Melanoma, Skin Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com